Thermo Fisher terminates deal for genetic testing firm Qiagen

Thermo Fisher had in July sweetened its offer, valuing the company at 11.3 billion euros ($13.38 billion) after pressure from some Qiagen investors, particularly after the German firm said it was seeing strong demand for products related to coronavirus testing. Thermo Fisher said the number of Qiagen shares tendered into the offer fell short of its threshold of 66.67%. As part of the sweetened offer, Thermo Fisher had reduced the minimum acceptance threshold from 75% of outstanding ordinary share capital. …read more

Source:: Yahoo Finance

      

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.